Array says early-stage diabetes drug looks promising
BOULDER, Colo. An early-stage clinical trial of an investigational drug for treating Type 2 diabetes met its main goals, the drug’s manufacturer announced this week.
Array BioPharma said the drug ARRY-403 reduced blood glucose following meals and fasting glucose over a 24-hour period in a phase 1 trial involving 41 patients who received doses ranging from 25 mg to 400 mg. The drug belongs to a class known as glucokinase activators, which rely on a glucose-sensing enzyme involved in metabolism of the blood sugar.
“These results are highly encouraging, validating this mechanism-of-action in Type 2 diabetic patients,” Array president and chief scientific officer Kevin Koch said in a statement. “Unlike current therapies, ARRY-403 enhances insulin production from the pancreas while simultaneously regulating glucose metabolism in the liver.”
Endo’s COO resigns
CHADDS FORD, Pa. The COO of generic drug company Endo Pharmaceuticals has announced her resignation, the company announced Wednesday.
Endo said COO Nancy Wysenski will resign effective Sept. 1 to attend to family matters.
“I thank Nancy Wysenski for her contributions to the successful transition of Endo over the past two years,” CEO David Holveck said in a statement. “She has been instrumental in supporting our strong revenue growth, the diversification of the business and in strengthening our commercial capabilities.”
AstraZeneca, Forest Labs to develop ceftaroline
NEW YORK Two drug companies have announced an agreement to develop a drug for treating drug-resistant bacterial infections.
New York-based Forest Labs and Anglo-Swedish drug maker AstraZeneca said Wednesday that they would work together to develop and commercialize ceftaroline in markets outside the United States, Canada and Japan.
The drug, currently in late-stage clinical trials, is designed to treat complicated skin structure infections and community-acquired bacterial pneumonia caused by bacteria such as methicillin-resistant Staphylococcus aureus and multi-drug resistant Streptococcus pneumoniae. Forest hopes to file an approval application with the Food and Drug Administration by the end of the year, while AstraZeneca hopes to file one for Europe by the end of next year.
Under the terms of the agreement, AstraZeneca will pay Forest a signing fee, royalties from sales and milestone payments and assume responsibility for development, approval and commercialization of ceftaroline in the areas covered by the agreement. Financial terms of the deal were not disclosed.